Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Northwest Bioth Cmn (NWBO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 128,405
  • Shares Outstanding, K 527,330
  • Annual Sales, $ 340 K
  • Annual Income, $ -73,140 K
  • 36-Month Beta 2.28
  • Price/Sales 16.57
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.16
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/15/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2277 +6.94%
on 01/24/19
0.2700 -9.81%
on 01/29/19
+0.0055 (+2.31%)
since 01/15/19
3-Month
0.1945 +25.19%
on 12/28/18
0.3151 -22.72%
on 12/11/18
+0.0295 (+13.79%)
since 11/15/18
52-Week
0.1700 +43.24%
on 04/26/18
0.3420 -28.80%
on 03/15/18
-0.0776 (-24.17%)
since 02/15/18

Most Recent Stories

More News
NW Bio Releases Voting Results From Annual Shareholders' Meeting

NWBO : 0.2540 (+4.31%)
Presentation By NWBio CEO At The Phacilitate Leaders World 2019 Conference

Focus on Complexity and Variability of Solid Tumors, and How DCVax(R)-L Addresses Them

NWBO : 0.2540 (+4.31%)
Presentation By NWBio CEO At The Phacilitate Leaders World 2019 Conference

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its CEO, Linda Powers, presented...

NWBO : 0.2540 (+4.31%)
NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax(R) personalized immune therapies for solid tumor cancers, announced that the package transaction involving...

NWBO : 0.2540 (+4.31%)
NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds

BETHESDA, Md. , Dec. 14, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...

NWBO : 0.2540 (+4.31%)
NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that the package transaction involving...

NWBO : 0.2540 (+4.31%)
NW Bio Announces Non-Dilutive Funding of Approximately $47.3 Million Through UK Property Transaction

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax(R) personalized immune therapies for solid tumor cancers, announced today that it has entered into agreements...

NWBO : 0.2540 (+4.31%)
NW Bio Announces Non-Dilutive Funding of Approximately $47.3 Million Through UK Property Transaction

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has entered into agreements...

NWBO : 0.2540 (+4.31%)
Growth Opportunities in Stocks Coming Off of Bottoms

HENDERSON, NV / ACCESSWIRE / November 27, 2018 / With the market in a bit of a swoon, many companies with positive 3rd quarter announcements have not yet seen them baked into the share price properly....

VKTX : 8.78 (-3.20%)
EMHTF : 2.6030 (+2.08%)
NWBO : 0.2540 (+4.31%)
OGRMF : 5.6300 (-1.57%)
DCTH : 0.3088 (-0.03%)
Northwest Biotherapeutics Releases Phase III Data for DCVax(R)-L and Secures New Financing

NEW YORK, NY / ACCESSWIRE / November 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

NWBO : 0.2540 (+4.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade NWBO with:

Key Turning Points

2nd Resistance Point 0.2632
1st Resistance Point 0.2533
Last Price 0.2540
1st Support Level 0.2373
2nd Support Level 0.2312

See More

52-Week High 0.3420
Fibonacci 61.8% 0.2763
Fibonacci 50% 0.2560
Last Price 0.2540
Fibonacci 38.2% 0.2357
52-Week Low 0.1700

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar